Morel et al., 2017 - Google Patents
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stabilityMorel et al., 2017
- Document ID
- 1714332454774090292
- Author
- Morel A
- Ginestier C
- Pommier R
- Cabaud O
- Ruiz E
- Wicinski J
- Devouassoux-Shisheboran M
- Combaret V
- Finetti P
- Chassot C
- Pinatel C
- Fauvet F
- Saintigny P
- Thomas E
- Moyret-Lalle C
- Lachuer J
- Despras E
- Jauffret J
- Bertucci F
- Guitton J
- Wierinckx A
- Wang Q
- Radosevic-Robin N
- Penault-Llorca F
- Cox D
- Hollande F
- Ansieau S
- Caramel J
- Birnbaum D
- Vigneron A
- Tissier A
- Charafe-Jauffret E
- Puisieux A
- Publication year
- Publication venue
- Nature medicine
External Links
Snippet
Chromosomal instability (CIN), a feature of most adult neoplasms from their early stages onward, is a driver of tumorigenesis. However, several malignancy subtypes, including some triple-negative breast cancers, display a paucity of genomic aberrations, thus …
- 206010006187 Breast cancer 0 title description 59
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morel et al. | A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability | |
| Ombrato et al. | Metastatic-niche labelling reveals parenchymal cells with stem features | |
| Lanfranca et al. | Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice | |
| Valenti et al. | Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors | |
| Chen et al. | DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis | |
| Liu et al. | MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells | |
| Bruna et al. | TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer | |
| Ke et al. | Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells | |
| Shafee et al. | Cancer stem cells contribute to cisplatin resistance in Brca1/p53–mediated mouse mammary tumors | |
| Li et al. | ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression | |
| Ganci et al. | PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma | |
| Sun et al. | MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2 | |
| Wang et al. | Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers | |
| Wang et al. | SIRT1-mediated expression of CD24 and epigenetic suppression of novel tumor suppressor miR-1185-1 increases colorectal cancer stemness | |
| Zhou et al. | LIN28B activation by PRL-3 promotes Leukemogenesis and a stem cell–like transcriptional program in AML | |
| Liu et al. | C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer | |
| Paulsson et al. | GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours | |
| Morris IV et al. | Dicer regulates differentiation and viability during mouse pancreatic cancer initiation | |
| Xu et al. | STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway | |
| Wang et al. | microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer | |
| Chen et al. | KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo–YAP pathway | |
| Lee et al. | Network inference analysis identifies SETDB1 as a key regulator for reverting colorectal cancer cells into differentiated normal-like cells | |
| D’Amato et al. | Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system | |
| Jung et al. | Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF‐β pathway | |
| Yang et al. | High expression of KITLG is a new hallmark activating the MAPK pathway in type A and AB thymoma |